Tag: lipid nanoparticle

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia...

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsLipid nanoparticle

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

Liftoff Announces Pricing of Initial Public Offering

Quantinuum Announces Pricing of Upsized Initial Public Offering

Tag: lipid nanoparticle

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us